Titan America SA, the US unit of Titan Cement International SA, has filed for an initial public offering in New York, showing ...

Weight-loss drug developer Metsera, backed by ARCH Venture Partners, revealed a wider loss in its paperwork for a U.S.

Antharas said it expects the IPO to price between $4 and $5 per share. The company applied to list on the Nasdaq Capital Market under the symbol AAS. For the year ended Dec. 31, 2023, the company ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

Gold jewellery maker Shanti Gold International has filed preliminary papers with SEBI to raise funds via initial public ...

Zepto is preparing to file for an IPO by March-April 2025 and has received approval to move its holding entity from Singapore ...

The IPO, with an equity share face value of ₹10, consists entirely of a fresh issuance of up to 18 million equity shares.

Metsera (MTSR), which is developing ultra-long-acting drugs for obesity, has filed for a $100M initial public offering. Read more here.

Venture Global is seeking up to $110.38 billion valuation in its New York initial public offering, the second-largest U.S.

Fintech giant Groww is reportedly gearing up to file for an initial public offering (IPO) in the next 10-12 months ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

The EV maker expects a spurt of 80% in value from previous funding. Zerodha cofounder Nikhil Kamath, an investor in the ...